Chakma Justin
SEC insider (Form 3/4/5 filer). CIK 0001951238. Chief Business Officer at ARS Pharmaceuticals, Inc. (SPRY). 25 reported Form 4/5 transactions since Sep 2024; latest on Jan 2, 2026. Located in SAN DIEGO, CA.
Companies Chakma Justin has filed insider reports for
- ARS Pharmaceuticals, Inc. (SPRY): Officer, Chief Business Officer
Chakma Justin
CIK: 0001951238
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARS Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
AwardDirectStock option (right to buy)
240K shares- - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
SaleDirect136.4K shares at avg. $8.86$1.2M - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
ExerciseDirect30K shares at avg. $0.84$25K - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
SaleDirect30K shares at avg. $8.91$267K - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
AwardDirectStock option (right to buy)
274.1K shares- - Dec 13, 2024SPRY
ARS Pharmaceuticals, Inc.
SaleDirect27.3K shares at avg. $12.06$329K - Dec 13, 2024SPRY
ARS Pharmaceuticals, Inc.
ExerciseDirect27.3K shares at avg. $1.44$39K - Dec 12, 2024SPRY
ARS Pharmaceuticals, Inc.
ExerciseDirect117.3K shares at avg. $0.84$99K - Dec 12, 2024SPRY
ARS Pharmaceuticals, Inc.
SaleDirect117.3K shares at avg. $12.27$1.4M - Dec 10, 2024SPRY
ARS Pharmaceuticals, Inc.
SaleDirect50K shares at avg. $13.15$658K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award Stock option (right to buy) | 240,000 | - | - | Direct |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale | 136,380 | $8.86 | $1,208,790 | Direct |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise | 30,000 | $0.84 | $25,200 | Direct |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale | 30,000 | $8.91 | $267,357 | Direct |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award Stock option (right to buy) | 274,100 | - | - | Direct |
| Dec 13, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale | 27,272 | $12.06 | $328,969 | Direct |
| Dec 13, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise | 27,272 | $1.44 | $39,272 | Direct |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise | 117,333 | $0.84 | $98,560 | Direct |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale | 117,333 | $12.27 | $1,439,124 | Direct |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $13.15 | $657,625 | Direct |
1-10 of 25 transactions